Biocon Limited (Biocon) is a global biopharmaceutical company. Biocon has 70 brands spread across six therapeutic segments: Diabetology, Oncotherapeutics, Nephrology, Cardiology, Immunotherapy and Comprehensive Care. The Company has a portfolio of active pharmaceutical ingredients (APIs), including generics, such as Statins, Immunosuppressants and products, such as Fidaxomicin. Its biologic brands include Herceptin, Enbrel, MabThera, Remicade, as well as Insulin Analogs, such as Lantus, Humalog and NovoLog. Its biopharmaceuticals products include active pharmaceutical ingredients (API) cardiovascular agents, such as Rosuvastatin, Atorvastatin, Pravastatin, Lovastatin, Fluvastatin and Simvastatin; biological include human insulin, insulin glargine, insulin lispro, insulin aspart, erythropoietin, granulocyte colony stimulating factor, streptokinase and monoclonal antibodies; branded formulations include diabetology, oncology, nephrology, cardiology, comprehensive care and immunotherapy.